bispecific antibody; bispecific monoclonal antibody

Indications

• relapsed/refractory multiple myeloma (FDA-approved) (teclistamab, talquetamab)
• precursor B-cell acute lymphoblastic leukemia (blinatumomab)
• treatment of hemophilia A (emicizumab)

Dosage

• intravenous or subcutaneous administration
• see individual antibody

Adverse effects

• treatment related adverse effects common (up to 80%)
• neutropenia (40%)
• anemia (28%)
• thrombocytopenia (20%)
• cytokine release syndrome (70%).

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• bispecific antibody
  • binds antigen on pathological cell & CD3 to redirect T cells to eliminate diseased cells

More general terms

• pharmaceutical monoclonal antibody

More specific terms

• blinatumomab (Blincyto)
• emicizumab-kxwh (Hemlibra, ACE910)
• talquetamab
• teclistamab-cqyv (Tecvayli)